Christine M. Lovly will spearhead the development of City of Hope’s new national thoracic oncology program, effective Jan. 1, 2026.
James B. Yu was named associate director for clinical research at Dartmouth Cancer Center.
Christine Lovly to lead City of Hope’s new national thoracic oncology program
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
YOU MAY BE INTERESTED IN
Eric Cantor was named the next president and chief executive officer of PhRMA, effective Nov. 9.
Researchers from City of Hope have developed a “plug-and-play” technology that adds engineered molecules to chimeric antigen receptor T cells after treatment, allowing scientists to better control the cells and redirect them to attack different types of cancer. The preclinical study offers a more flexible way to help CAR T cells keep pace with mutating tumors.
What should a cancer center look like in an era of AI, genomics, complex patient populations, rising costs, and declining public trust in science?
Breast cancer treatment has changed dramatically over the past decade. One of the most important advances has been our growing ability to understand the biology of each patient’s cancer and use those insights to guide treatment decisions more precisely. That shift is helping make personalized cancer care a reality.
Heidi Overton, President Trump’s nominee for FDA Commissioner, defended the agency’s recent policy decisions reversing its hardball stance on flavored nicotine products, as she appeared in front of the Senate Committee on Health, Education, Labor, and Pensions on Sept 24.
